155 related articles for article (PubMed ID: 30919295)
1. Towards a More User-Friendly Medication Information Delivery to People Living with Multiple Sclerosis: A Case Study with Alemtuzumab.
Azman A; Poyade M; Overell J
Adv Exp Med Biol; 2019; 1120():67-82. PubMed ID: 30919295
[TBL] [Abstract][Full Text] [Related]
2. Alemtuzumab in the treatment of multiple sclerosis: patient selection and special considerations.
Dörr J; Baum K
Drug Des Devel Ther; 2016; 10():3379-3386. PubMed ID: 27799738
[TBL] [Abstract][Full Text] [Related]
3. Acute sarcoidosis in a multiple sclerosis patient after alemtuzumab treatment.
Graf J; Ringelstein M; Lepka K; Schaller J; Quack H; Hartung HP; Aktas O; Albrecht P
Mult Scler; 2018 Nov; 24(13):1776-1778. PubMed ID: 30307371
[TBL] [Abstract][Full Text] [Related]
4. ALAIN01--Alemtuzumab in autoimmune inflammatory neurodegeneration: mechanisms of action and neuroprotective potential.
Ruck T; Afzali AM; Lukat KF; Eveslage M; Gross CC; Pfeuffer S; Bittner S; Klotz L; Melzer N; Wiendl H; Meuth SG
BMC Neurol; 2016 Mar; 16():34. PubMed ID: 26966029
[TBL] [Abstract][Full Text] [Related]
5. [Updated recommendations of the Council of Experts on the use and safety of alemtuzumab (Lemtrada)].
Khachanova NV; Bakhtiyarova KZ; Boyko AN; Vlasov YV; Davydovskaya MV; Evdoshenko EP; Zakharova MN; Kotov SV; Popova EV; Sivertseva SA; Totolyan NA; Khabirov FA
Zh Nevrol Psikhiatr Im S S Korsakova; 2020; 120(3):82-91. PubMed ID: 32323949
[TBL] [Abstract][Full Text] [Related]
6. Sarcoidosis following alemtuzumab treatment for multiple sclerosis.
Willis MD; Hope-Gill B; Flood-Page P; Joseph F; Needham E; Jones J; Coles A; Robertson NP
Mult Scler; 2018 Nov; 24(13):1779-1782. PubMed ID: 30307364
[TBL] [Abstract][Full Text] [Related]
7. Alemtuzumab (LEMTRADA) and multiple sclerosis. Biased evaluation, evidence of serious risks.
Prescrire Int; 2015 Mar; 24(158):69. PubMed ID: 25897458
[TBL] [Abstract][Full Text] [Related]
8. Alemtuzumab and multiple sclerosis: therapeutic application.
Minagar A; Alexander JS; Sahraian MA; Zivadinov R
Expert Opin Biol Ther; 2010 Mar; 10(3):421-9. PubMed ID: 20095876
[TBL] [Abstract][Full Text] [Related]
9. [Clinical recommendations on the use of alemtuzumab (lemtrada)].
Alifirova VM; Bisaga GN; Boyko AN; Bryukhov VV; Davydovskay MV; Zakharova MN; Zakharova EV; Malkova NA; Popova EV; Salogub GN; Sivertseva SA; Troshina EA; Khachanova NV; Schmidt TE
Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(2. Vyp. 2):115-126. PubMed ID: 28617370
[No Abstract] [Full Text] [Related]
10. Update on disease-modifying therapies for multiple sclerosis.
Vargas DL; Tyor WR
J Investig Med; 2017 Jun; 65(5):883-891. PubMed ID: 28130412
[TBL] [Abstract][Full Text] [Related]
11. Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond.
Ruck T; Bittner S; Wiendl H; Meuth SG
Int J Mol Sci; 2015 Jul; 16(7):16414-39. PubMed ID: 26204829
[TBL] [Abstract][Full Text] [Related]
12. Alemtuzumab Use in Clinical Practice: Recommendations from European Multiple Sclerosis Experts.
Berger T; Elovaara I; Fredrikson S; McGuigan C; Moiola L; Myhr KM; Oreja-Guevara C; Stoliarov I; Zettl UK
CNS Drugs; 2017 Jan; 31(1):33-50. PubMed ID: 27882532
[TBL] [Abstract][Full Text] [Related]
13. Management of immune thrombocytopenia in multiple sclerosis patients treated with alemtuzumab: a Belgian consensus.
Lambert C; Dubois B; Dive D; Lysandropoulos A; Selleslag D; Vanopdenbosch L; Van Pesch V; Vanwijmeersch B; Janssens A
Acta Neurol Belg; 2018 Mar; 118(1):7-11. PubMed ID: 29380254
[TBL] [Abstract][Full Text] [Related]
14. Depletion of CD52-positive cells inhibits the development of central nervous system autoimmune disease, but deletes an immune-tolerance promoting CD8 T-cell population. Implications for secondary autoimmunity of alemtuzumab in multiple sclerosis.
von Kutzleben S; Pryce G; Giovannoni G; Baker D
Immunology; 2017 Apr; 150(4):444-455. PubMed ID: 27925187
[TBL] [Abstract][Full Text] [Related]
15. Alemtuzumab for Multiple Sclerosis.
Willis MD; Robertson NP
Curr Neurol Neurosci Rep; 2016 Sep; 16(9):84. PubMed ID: 27485945
[TBL] [Abstract][Full Text] [Related]
16. Cytomegalovirus primary infection in a patient with multiple sclerosis treated with alemtuzumab.
Aguirre C; Meca-Lallana V; Sánchez P; Vivancos J
Mult Scler Relat Disord; 2019 Oct; 35():270-271. PubMed ID: 31442904
[TBL] [Abstract][Full Text] [Related]
17. Thyroid disorders in alemtuzumab-treated multiple sclerosis patients: a Belgian consensus on diagnosis and management.
Decallonne B; Bartholomé E; Delvaux V; D'haeseleer M; El Sankari S; Seeldrayers P; Van Wijmeersch B; Daumerie C
Acta Neurol Belg; 2018 Jun; 118(2):153-159. PubMed ID: 29372482
[TBL] [Abstract][Full Text] [Related]
18. Severe B cell-mediated disease activation despite two cycles of alemtuzumab in a patient with multiple sclerosis.
Hyun JW; Kim Y; Kim G; Kim SH; Kim HJ
Mult Scler; 2019 Dec; 25(14):1942-1945. PubMed ID: 30403365
[TBL] [Abstract][Full Text] [Related]
19. Severe CNS inflammation after discontinuation of natalizumab and start of daclizumab successfully treated with alemtuzumab.
Hümmert MW; Deppe J; Pul R; Wurster U; Schwenkenbecher P; Sühs KW; Bronzlik P; Stangel M; Skripuletz T
Mult Scler Relat Disord; 2018 May; 22():87-89. PubMed ID: 29631243
[TBL] [Abstract][Full Text] [Related]
20. [Alemtuzumab therapy 2017].
Biernacki T; Bencsik K; Sandi D; Vécsei L
Ideggyogy Sz; 2017 Nov; 70(11-12):371-380. PubMed ID: 29870645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
